Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact

Tracking T cells

The infiltration of T cells into tumors is considered beneficial for the rejection of malignantly transformed cells. In particular, cytotoxic T lymphocytes (CTLs) are thought to destroy tumor cells and secrete cytokines that activate other effector T cell populations; however, recent evidence suggests that many infiltrating tumor-reactive CTLs are dysfunctional and exhibit features common in T cell exhaustion. Christian Bauer, Edward Kim, and colleagues at Harvard Medical School developed a murine model of adoptive T cell therapy to track T cell populations within tumor tissue. Using this model, the authors determined that regulatory T cells (Tregs) mediate the induction of an exhaustion-like phenotype in tumor-specific CTLs that corresponds with impaired cytotoxicity and cytokine release. Tumor antigen-specific Tregs were initially activated in the draining lymph node, where they expanded prior to migrating to the tumor. Within tumors, Tregs interacted with antigen presenting cells (APCs), decreasing expression of co-stimulatory molecules on the APC surface. The interaction of Treg-modulated APCs with tumor CLTs directly suppressed CTL function, resulting in upregulation of the co-inhibitory molecules PD1 and TIM3. The accompanying multiphoton intravital microscopy image shows CTLs (green) at the border between tumor parenchyma (blue) and stroma. The tumor vasculature (red) was labeled by i.v. injection of quantum dots.

Published May 8, 2014, by Corinne Williams

Scientific Show Stopper

Related articles

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction
Christian A. Bauer, … , Natalie M. Claudio, Thorsten R. Mempel
Christian A. Bauer, … , Natalie M. Claudio, Thorsten R. Mempel
Published May 8, 2014
Citation Information: J Clin Invest. 2014;124(6):2425-2440. https://doi.org/10.1172/JCI66375.
View: Text | PDF
Research Article Oncology

Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction

  • Text
  • PDF
Abstract

Tregs control various functions of effector T cells; however, where and how Tregs exert their immunomodulatory effects remain poorly understood. Here we developed a murine model of adoptive T cell therapy and found that Tregs induce a dysfunctional state in tumor-infiltrating CTLs that resembles T cell exhaustion and is characterized by low expression of effector cytokines, inefficient cytotoxic granule release, and coexpression of coinhibitory receptors PD-1 and TIM-3. Induction of CTL dysfunction was an active process, requiring local TCR signals in tumor tissue. Tregs infiltrated tumors only subsequent to Ag-dependent activation and expansion in tumor-draining LNs; however, Tregs also required local Ag reencounter within tumor tissue to induce CTL dysfunction and prevent tumor rejection. Multiphoton intravital microscopy revealed that in contrast to CTLs, Tregs only rarely and briefly interrupted their migration in tumor tissue in an Ag-dependent manner and formed unstable tethering-interactions with CD11c+ APCs, coinciding with a marked reduction of CD80 and CD86 on APCs. Activation of CTLs by Treg-conditioned CD80/86lo DCs promoted enhanced expression of both TIM-3 and PD-1. Based on these data, we propose that Tregs locally change the costimulatory landscape in tumor tissue through transient, Ag-dependent interactions with APCs, thus inducing CTL dysfunction by altering the balance of costimulatory and coinhibitory signals these cells receive.

Authors

Christian A. Bauer, Edward Y. Kim, Francesco Marangoni, Esteban Carrizosa, Natalie M. Claudio, Thorsten R. Mempel

×
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts